Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Up 2.4%

GILD opened at $127.23 on Wednesday. The company’s 50 day moving average is $132.61 and its 200-day moving average is $134.32. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a market cap of $157.96 billion, a P/E ratio of 17.33 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the company posted $1.81 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention, advancing a potential new long-acting PrEP option and opening a possible new growth driver for the company. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, signaling continued analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Two Gilead insiders, including CFO Andrew D. Dickinson and Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. The sales were disclosed normally and do not appear to signal an abrupt change in outlook, but they can still weigh on sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
• Neutral Sentiment: Recent reports noted GILD had previously dipped modestly in the prior session, but the stock’s latest move appears tied more to the FDA milestone and analyst support than to broader market action. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently made changes to their positions in GILD. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after purchasing an additional 26,882 shares during the period. Aviva PLC lifted its position in shares of Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after acquiring an additional 59,782 shares during the period. NewEdge Wealth LLC lifted its position in shares of Gilead Sciences by 2.9% during the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after acquiring an additional 17,284 shares during the period. Nordea Investment Management AB lifted its position in shares of Gilead Sciences by 16.5% during the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after acquiring an additional 726,101 shares during the period. Finally, Life Cycle Investment Partners Ltd acquired a new position in shares of Gilead Sciences during the 4th quarter valued at $1,418,000. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Wednesday, May 20th. Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a research note on Monday, June 8th. Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Citigroup raised their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Barclays initiated coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price on the stock. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.